Last reviewed · How we verify
ETH47
ETH47 is a small molecule that targets the SARS-CoV-2 main protease.
ETH47 is a small molecule that targets the SARS-CoV-2 main protease. Used for Treatment of COVID-19.
At a glance
| Generic name | ETH47 |
|---|---|
| Sponsor | Ethris GmbH |
| Drug class | SARS-CoV-2 main protease inhibitor |
| Target | SARS-CoV-2 main protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
ETH47 works by binding to the SARS-CoV-2 main protease, thereby inhibiting viral replication. This mechanism of action is crucial for the treatment of COVID-19. ETH47 has shown promise in preclinical studies, but further research is needed to confirm its efficacy and safety.
Approved indications
- Treatment of COVID-19
Common side effects
- Nausea
- Headache
- Fatigue
Key clinical trials
- Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus Challenge (PHASE2)
- A Phase 1, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of ETH47 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ETH47 CI brief — competitive landscape report
- ETH47 updates RSS · CI watch RSS
- Ethris GmbH portfolio CI